New drug combo offers hope for patients with Tough-to-Treat lymphoma
NCT ID NCT06723457
First seen Feb 18, 2026 · Last updated May 10, 2026 · Updated 11 times
Summary
This study tests whether combining two immune-boosting drugs, epcoritamab and lenalidomide, can shrink or eliminate lymphoma in 34 patients whose cancer did not respond to prior treatment or came back. The participants have a type of lymphoma linked to a weakened immune system, such as after an organ transplant. The goal is to see if this combination leads to a complete disappearance of cancer within six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.